Ruggeri B A, Huang L, Berger D, Chang H, Klein-Szanto A J, Goodrow T, Wood M, Obara T, Heath C W, Lynch H
Department of Pathology and Laboratory Medicine, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania 19102, USA.
Cancer. 1997 Feb 15;79(4):700-16.
The molecular pathology underlying the development and progression of ductal pancreatic adenocarcinoma is poorly understood relative to that of other major cancers in industrialized societies. The frequency, nature, and distribution of p53 abnormalities, their temporal relationship to the metastatic and clinicopathologic phenotypes of sporadic and familial pancreatic cancer, and their consequent effects on the genetics and expression of critical wild-type p53-regulated genes (mdm-2 and p21/WAF-1) warrant examination in pancreatic adenocarcinoma. This molecular and immunochemical study of the p53, mdm-2, and p21/ WAF-1 genes and gene products examined the largest series of nonneoplastic, neoplastic, and metastatic ductal pancreatic lesions reported to date in relation to clinicopathologic profile.
Histologically confirmed specimens of primary (n = 136) and metastatic (n = 23) sporadic and familial ductal pancreatic adenocarcinoma lesions were subjected to immunochemical analyses of p53 expression in which a panel of 3 antibodies was utilized. A panel of nonneoplastic but histologically abnormal pancreatic lesions (n = 77) from individuals with varied histories of cigarette smoking were subjected to similar immunohistochemical examinations. In addition, 3 specimens from patients with chronic pancreatitis, 2 specimens of normal fetal pancreata, and 16 specimens of normal adult pancreata were examined as control tissues. Suitable frozen and archival microdissected tumor lesions were evaluated for mutations in exons 4-9 of the p53 gene by single strand conformation polymorphism (SSCP) and dideoxy sequencing analyses in which two distinct sets of outer and nested intron-based amplification primers were used for each exon. A subset of 25 tumor specimens and 18 tumor-derived cell lines for which the p53 mutation status was known were examined for amplification and/or overexpression of the mdm-2 gene; amplification was determined by Southern hybridization and overexpression by immunohistochemical and Western blot analyses. Similarly, mutations in the coding region of p21/WAF-1 gene were examined by SSCP and DNA sequence analyses, and steady-state expression of the p21/WAF-1 protein was assessed by Western blot analysis in these subsets of tumors and tumor-derived cell lines.
Positive ductal nuclear p53 immunostaining was demonstrated in 56% of primary tumors and 54% of metastatic lesions. The frequency did not differ significantly between sporadic and familial lesions, and immunostaining was not observed in ductal, acinar, or islet cell elements of normal pancreata or histologically abnormal benign pancreatic lesions from cigarette smokers. A total of 70% of tumor samples revealed reproducible SSCP abnormalities for p53; 42% of these were found in exons 7 and 8. DNA sequence analysis of cases with greater than 35% epithelial cellularity (n = 25) revealed 17 missense mutations, 12 of which were transitions. Seventy-five percent of these transitions were of G:C-->A:T type. A total of 22% of the p53 mutations identified were microdeletions, along with one insertional mutation at exon 8. None of the normal pancreata from sporadic or familial lesions revealed germ-line p53 alterations. Moreover, the frequency and spectra of p53 alterations exhibited no clear, statistically significant association with tumor grade, TNM stage, or patients' cigarette-smoking histories. The mdm-2 gene was neither amplified nor overexpressed immunochemically in a subset of ductal adenocarcinomas, and there was no clear relationship between the p53 mutation status and the status of the mdm-2 gene or protein. Similarly, SSCP and DNA sequence analysis of the p21/WAF-1 gene revealed only 2 genetic abnormalities in a series of 25 primary tumors and 15 tumor-derived cell lines; 1 of the cell lines also revealed the absence of immunoreactive p21/WAF-1 protein...
相对于工业化社会中的其他主要癌症,导管胰腺腺癌发生和进展的分子病理学仍了解甚少。p53异常的频率、性质和分布,它们与散发性和家族性胰腺癌转移及临床病理表型的时间关系,以及它们对关键野生型p53调控基因(mdm-2和p21/WAF-1)的遗传学和表达的后续影响,均值得在胰腺腺癌中进行研究。这项关于p53、mdm-2和p21/WAF-1基因及基因产物的分子和免疫化学研究,针对迄今报道的与临床病理特征相关的最大系列非肿瘤性、肿瘤性和转移性导管胰腺病变进行了检测。
对组织学确诊的原发性(n = 136)和转移性(n = 23)散发性及家族性导管胰腺腺癌病变标本进行p53表达的免疫化学分析,使用了一组3种抗体。对来自有不同吸烟史个体的一组非肿瘤性但组织学异常的胰腺病变(n = 77)进行类似的免疫组织化学检查。此外,检查了3例慢性胰腺炎患者的标本、2例正常胎儿胰腺标本和16例正常成人胰腺标本作为对照组织。通过单链构象多态性(SSCP)和双脱氧测序分析,对合适的冷冻及存档显微切割肿瘤病变进行p53基因第4至9外显子的突变评估,每个外显子使用两组不同的基于外显子和内含子的外部及巢式扩增引物。对已知p53突变状态的25个肿瘤标本和18个肿瘤衍生细胞系的子集进行mdm-2基因扩增和/或过表达检测;通过Southern杂交确定扩增情况,通过免疫组织化学和Western印迹分析确定过表达情况。同样,通过SSCP和DNA序列分析检测p21/WAF-1基因编码区的突变,并通过Western印迹分析评估这些肿瘤和肿瘤衍生细胞系子集中p21/WAF-1蛋白的稳态表达。
56%的原发性肿瘤和54%的转移性病变中显示导管细胞核p53免疫染色呈阳性。散发性和家族性病变之间的频率无显著差异,正常胰腺的导管、腺泡或胰岛细胞成分或吸烟所致组织学异常的良性胰腺病变中未观察到免疫染色。总共70%的肿瘤样本显示p53有可重复的SSCP异常;其中42%见于第7和8外显子。对上皮细胞含量大于35%的病例(n = 25)进行DNA序列分析,发现17个错义突变,其中12个是转换。这些转换中75%是G:C→A:T类型。所鉴定的p53突变中总共22%是微缺失,还有1个第8外显子的插入突变。散发性或家族性病变的正常胰腺均未发现种系p53改变。此外,p53改变的频率和谱与肿瘤分级、TNM分期或患者吸烟史无明显的统计学显著关联。在一部分导管腺癌中,mdm-2基因既未扩增也未免疫化学过表达,p53突变状态与mdm-2基因或蛋白状态之间无明确关系。同样,对p21/WAF-1基因的SSCP和DNA序列分析显示,在一系列25个原发性肿瘤和15个肿瘤衍生细胞系中仅发现2个基因异常;其中1个细胞系还显示无免疫反应性p21/WAF-1蛋白……